A log-rank type test to compare net survival distributions by Grafféo, Nathalie et al.
A log-rank type test to compare net survival
distributions
Nathalie Graffe´o, Fabienne Castell, Aure´lien Belot, Roch Giorgi
To cite this version:
Nathalie Graffe´o, Fabienne Castell, Aure´lien Belot, Roch Giorgi. A log-rank type test to
compare net survival distributions. 2015. <hal-01218237>
HAL Id: hal-01218237
https://hal.archives-ouvertes.fr/hal-01218237
Submitted on 22 Oct 2015
HAL is a multi-disciplinary open access
archive for the deposit and dissemination of sci-
entific research documents, whether they are pub-
lished or not. The documents may come from
teaching and research institutions in France or
abroad, or from public or private research centers.
L’archive ouverte pluridisciplinaire HAL, est
destine´e au de´poˆt et a` la diffusion de documents
scientifiques de niveau recherche, publie´s ou non,
e´manant des e´tablissements d’enseignement et de
recherche franc¸ais ou e´trangers, des laboratoires
publics ou prive´s.
Biometrics 000, 1–20 DOI: 000
000 0000
A log-rank type test to compare net survival distributions
Nathalie Graffe´o1,2, Fabienne Castell3, Aure´lien Belot4,5,6, and Roch Giorgi1,2,7,∗
1INSERM, UMR912 ” Economics and Social Sciences Applied to Health & Analysis of Medical Information ”
(SESSTIM), 13006 Marseille, France
2Aix Marseille University, UMR S912, IRD, 13006, Marseille, France
3Aix Marseille University, CNRS, Centrale Marseille, I2M, UMR 7373, 13453 Marseille, France
4Hospices Civils de Lyon, Service de Biostatistique, Lyon, France
5University Lyon 1, UMR 5558 Laboratoire Biostatistique-Sante´, , Villeurbanne, France
6Institut de Veille Sanitaire, DMCT, Saint-Maurice, France
7APHM, Hoˆpital Timone, BIOSTIC, Marseille, France
*email: roch.giorgi@univ-amu.fr
Summary: In population-based cancer studies, it is often of interest to compare cancer survival between different
populations. However, in such studies the exact causes of death are often unavailable or unreliable. Net survival
methods were developed to overcome this difficulty. Net survival is the survival that would be observed, in a
hypothetical world, if the studied disease were the only possible cause of death. The Pohar-Perme estimator (PPE)
is a non-parametric consistent estimator of net survival. In this paper, we present a log-rank-type test for comparing
net survival functions estimated by this estimator between several groups. We expressed our test in the counting
process framework to introduce the inverse probability weighting procedure as done in the PPE. We built a stratified
version to control for categorical covariates affecting the outcome. Simulation studies were performed to evaluate the
performance of our test and an application on real data is provided.
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1. Introduction
Net survival, the survival associated to the excess mortality hazard, is the survival observed
in an hypothetical world where the disease of interest would be the only possible cause
of death. The observed survival, which is the most frequently used, is the result of two
main survival components. One part comes from the studied disease whereas the second
part comes from all other causes that we are all exposed (Este`ve et al., 1990; Perme, Stare,
and Este`ve, 2012). On one hand, the observed survival do not distinguish between death
from the disease of interest (or excess death) and death from other causes. On the other
hand, net survival evaluates the burden of this disease independently of the differences in
general population mortality given by life tables, that is to say the mortality due to other
causes. In cancer research, the idea of net cancer survival is to study the proportion of
cancer deaths, that is to say patients dying, directly or indirectly, from cancer. So, this
epidemiological indicator, routinely estimated in cancer registries and in population-based
studies (see e.g. the EUROCARE program (De Angelis et al., 2014), the US SEER program
(Howlader et al., 2011) or the CONCORD programme (Allemani et al., 2015)), is crucial
for comparison between different populations (Perme et al., 2012; Danieli et al., 2012). For
instance, when comparing patterns of care between countries, it is essential to take into
account the general population mortality because of its weight on observed survival.
In population-based studies the exact causes of death are often unavailable and, when
available, it is often difficult to state whether they are disease related (Berkson and Gage,
1950). Net survival methods were developed to overcome this difficulty (Este`ve et al., 1990).
Historically, several non-parametric estimators have been proposed to estimate net survival
(Ederer and Heise, 1959; Ederer, Axtell, and Cutler, 1961; Hakulinen, 1982). But in 2012
Perme et al. (2012) argued that, in most cases, these estimators do not estimate net survival.
They proposed a non-parametric estimator that corrects the Ederer II estimator (Ederer and
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Heise, 1959) which is biased due to informative censoring. For instance, excess mortality and
other causes mortality share the influence of age leading to informative censoring. So Perme
et al. used population mortality information to weight and correct for those who left the
sample due to deaths of other causes. In addition, Danieli et al. (2012) showed by a simulation
study that the Pohar-Perme estimator (PPE) is a consistent non-parametric estimator of net
survival, which may be preferred to the other existing non-parametric estimators. The PPE
assesses a hypothetical quantity which allows comparison across populations. However, to
the best of our knowledge, it is not yet possible to compare distributions of net survival
over a given period. We can only compare two estimates at a given time t with a classical
Z-test. Besides in the parametric framework, we could use a likelihood ratio test from the
multivariate excess mortality model (see e.g. Remontet et al., 2007) to compare net survival
between 2 or more groups, but it requires some complex model building strategy.
In this paper, we propose a log-rank type test to compare distributions of net survival
estimated by the PPE between at least 2 groups over a defined follow-up period. This choice
was made for several reasons. First, the log-rank test (Mantel, 1966; Peto and Peto, 1972)
is the most commonly used test to compare distributions of observed survival between at
least two groups. Secondly, the log-rank test uses the cumulative hazard function and can
be represented with stochastic processes (Aalen, Borgan, and Gjessing, 2008; Fleming and
Harrington, 2011; Andersen, Borgan, Gill, and Keiding, 1993). Finally, because the PPE is
developed on that scale and is written with stochastic processes, the log-rank test allows to
introduce easily the weights of the PPE in the corresponding counting processes.
In section 2 we present the building of our proposed log-rank type test and the stratified
version of this test in Section 3. Section 4 presents a simulation study where we investigated
the performance of our test and Section 5 provides an application to a colorectal cancer data
set. We conclude this paper with a brief discussion.
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2. A log-rank type test for k ! 2 groups
The proposed test compares the distribution of net survival estimated by the PPE (Perme
et al., 2012) between k ! 2 groups over a defined follow-up period. Assume that observations
are made on nh patients from group h with h ∈ [[1; k]] and k ! 2. Let n =
k∑
h=1
nh denote the
total number of patients. Let’s also assume (Fleming, Harrington, and O’sullivan, 1987)
∀h ∈ [[1; k]], lim
n→∞
nh
n
= αh;αh ∈ ]0; 1[ .
Note that under these assumptions: lim
n→∞
min
h
nh =∞.
2.1 Notations and model
For each patient i in the group h, we consider that the time to death, Th,i, is the minimum
of two distinct times: TPh,i due to ”population hazard” and TEh,i due to ”excess hazard”.
Let Ch,i denote the time to censoring and define Uh,i = min(Th,i, Ch,i) the follow-up time of
patient i. δ˜h,i denotes the failure indicator equal to 1 if the true failure time, Th,i, is observed
and 0 if patient i is censored. Each patient i in a group h has covariates denoted by the
vector Xh,i. Dh,i is a sub-vector of Xh,i describing all the demographic covariates so that
Xh,i \Dh,i and TPh,i are independent. We take the same set of assumptions as in Perme
et al. (2012) that is :
(1) (TPh,i, TEh,i , Ch,i,Xh,i)h,i are mutually independent;
(2) (TPh,i, TEh,i , Ch,i,Xh,i)i have the same distribution;
(3) TEh,i and TPh,i are conditionally independent given Xh,i;
(4) censoring times Ch,i are independent of the pair (Th,i,Xh,i).
Further, we assume that the censoring process is non informative i.e. SC,h(t) := P (Ch,i > t)
(∀i ∈ [[1;n]], ∀h ∈ [[1; k]]). The observed data are given by (Uh,i, δ˜h,i,Xh,i)h,i for each patient
i in group h. The conditional net survival function of TEh,i corresponding to every patient
i belonging to group h is denoted by S˜E,h,i(t) = P (TEh,i > t | Xh,i). The corresponding
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conditional cumulative excess hazard is denoted by Λ˜E,h,i. In the same way, we can define
the conditional population all-cause survival as S˜P,h,i(t) = P (TPh,i > t | Xh,i) which
equals P (TPh,i > t | Dh,i) since Xh,i \ Dh,i and TPh,i are assumed to be independent.
The corresponding conditional population all-cause cumulative hazard is denoted by Λ˜P,h,i.
We use life tables to calculate conditional population all-cause hazard functions according to
individual demographic covariates such as age, sex and year of diagnosis that can be found
inDh,i. We assume that these life tables describe adequately the all-cause death rates in the
study population (Perme et al., 2012). Further, for each group h, the net survival function is
defined as SE,h(t) = E(S˜E,h,1(t)) and thus we have SE,h(t) = P (TEh,1 > t). Let ΛE,h denote
the corresponding cumulative excess hazard. In the same way, we define the population
all-cause survival by SP,h(t) = P (TPh,1 > t) and the corresponding population all-cause
cumulative hazard by ΛP,h. Note that λ˜E,h,i, λ˜P,h,i, λE,h and λP,h denote the instantaneous
hazards related to Λ˜E,h,i, Λ˜P,h,i, ΛE,h and ΛP,h respectively. We assumed that the conditional
observed mortality hazard is the sum of the conditional population mortality hazard and the
conditional excess mortality hazard:
λ˜P,h,i(t) + λ˜E,h,i(t).
Besides, we will also use the following additional assumptions to prove the asymptotic χ2
distribution of our test statistic under the null:
a)
∫ T
0
SE,h(s)λ
2
E,h(s)ds <∞,
b) ∀h ∈ [[1; k]], E(
1
S˜P,h,1(T )3
) <∞, (1)
c) ∀h ∈ [[1; k]], E(
∫ T
0
λ˜P,h,1(s)2ds
S˜P,h,1(s)3
) <∞.
where T is a constant denoting the maximum follow-up time. Note that these assumptions
require that T is not too long compared with TP or TE . For instance, a) is not satisfied if
TE < T (a.s.) and b) is not satisfied if TP < T (a.s.).
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2.2 The log-rank type statistic
The usual log-rank test compares k cumulative observed hazard functions over [0, T ]. Let
[0, T ] denote the period of observation. The k-sample log-rank test is a test for the null
hypothesis
(H0) : ∀t ∈ [0, T ] , Λ1(t) = . . . = Λk(t) where k ! 2 is the number of groups to compare and
Λh (h ∈ [[1; k]]) is the cumulative observed hazard. Using counting process representations
(see e.g. Andersen et al., 1993), the log-rank test is based on the following statistic:
Zh(T ) =
∫ T
0
1(Y.(s) > 0)dNh(s)−
∫ T
0
1(Y.(s) > 0)
Yh(s)
Y.(s)
dN.(s),
where h ∈ [[1; k]], Nh,i(s) = 1(Th,i " s, Th,i " Ch,i) = 1(Uh,i " s, δ˜h,i = 1),
Yh,i(s) = 1(Th,i ! s, Ch,i ! s), Nh(s) =
nh∑
i=1
Nh,i(s), Yh(s) =
nh∑
i=1
Yh,i(s), Y.(s) =
k∑
h=1
Yh(s)
and N.(s) =
k∑
h=1
Nh(s) for k ! 2. Zh(T ) represents the difference between the number of
observed deaths in the group h and the corresponding expected values.
Here, our goal is to test the null hypothesis
(H0) : ∀t ∈ [0, T ] , ΛE,1(t) = . . . = ΛE,k(t)
where k ! 2. More precisely, we want to compare k cumulative excess hazard functions over
this period using PPE (Perme et al., 2012). The PPE, ΛˆE,h, is a consistent estimator of
ΛE,h. It corrects the Ederer II estimator for those who left the sample due to deaths of other
causes using the inverse probability weighting procedure (Robins, 1993). The weights are the
survival probabilities of other causes and are applied to the counting and the at-risk processes.
More precisely, we have dNwh,i(s) =
dNh,i(s)
S˜P,h,i(s)
, Y wh,i(s) =
Yh,i(s)
S˜P,h,i(s)
, Nwh (s) =
nh∑
i=1
Nwh,i(s), and
Y wh (s) =
nh∑
i=1
Y wh,i(s) for h ∈ [[1; k]] and k ! 2. The PPE is given by:
∀k ! 2, ∀h ∈ [[1; k]], ΛˆE,h(t) =
∫ t
0
dNwh (s)
Y wh (s)
−
∫ t
0
∑nh
i=1 Y
w
h,i(s)λ˜P,h,i(s)ds
Y wh (s)
.
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To build our log-rank type test, we first have to consider another stochastic process related to
the expected number of deaths due to cancer NE,h(s) =
nh∑
i=1
NE,h,i(s) where NE,h,i(s) is given
by Nh,i(s)−
∫ s
0
Yh,i(u)λ˜P,h,i(u)du for each patient i and for each group h ∈ [[1; k]]. Second, we
use the same weighting procedure as in the PPE. The expected weighted number of deaths
due to cancer is then defined by NwE,h(s) =
nh∑
i=1
NwE,h,i(s) with dN
w
E,h,i(s) =
dNE,h,i(s)
S˜P,h,i(s)
. For
all h ∈ [[1; k]], we now consider the statistic
Zwh (T ) =
∫ T
0
1(Y w. (s) > 0)dN
w
E,h(s)−
∫ T
0
1(Y w. (s) > 0)
Y wh (s)
Y w. (s)
dNwE,.(s), (2)
where Y w. (s) =
k∑
h=1
Y wh (s) and dN
w
E,.(s) =
k∑
h=1
dNwE,h(s) for k ! 2.
Note that when k = 2, Zw
1
(T ) is given by∫ T
0
1(Y w. (s) > 0)dN
w
E,1(s)−
∫ T
0
1(Y w. (s) > 0)
Y w1 (s)
Y w
1
(s) + Y w
2
(s)
(
dNwE,1(s) + dN
w
E,2(s)
)
=
∫ T
0
1(Y w. (s) > 0)
(
Y w2 (s)
Y w
1
(s) + Y w
2
(s)
dNwE,1(s)−
Y w1 (s)
Y w
1
(s) + Y w
2
(s)
dNwE,2(s)
)
.
The proposed test will be called log-rank type test because of the similarity between the two
tests. For h ∈ [[1; k]],
dNwE,h(s)
Y wh (s)
is a consistent estimator of the instantaneous excess hazard
at time s, λE,h(s) (Perme et al., 2012). It serves the same purpose as
dNh(s)
Yh(s)
which is a
consistent estimator of the instantaneous observed hazard at time s, λh(s).
2.3 Estimate of the variance of Zwh under the null
We used martingale theory to estimate the variance of the statistic Zwh (T ) under the null.
We start by looking at the case where TEh andXh are independent for each h ∈ [[1; k]] i.e. we
assume homogeneity in each group. This is a strong assumption usually made when studying
the usual log-rank test (see e.g. Andersen et al., 1993). This assumption is frequently violated
in practice, for example when cancer death is related to sex of patients. Then TE and X are
dependent. We will deal with this general case by building a stratified test presented in the
next section.
Following the idea of the calculation of the estimate of the variance of the PPE (Perme et al.,
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2012), we introduce
Mh,i(s)
def
= Nh,i(s)−
∫ s
0
Yh,i(u)
(
λ˜P,h,i(u) + λE,h(u)
)
du
= NE,h,i(s)−
∫ s
0
Yh,i(u)λE,h(u)du.
Mh,i(s) is a local square integrable martingale with respect to the filtration
Fs = σ (Xh,i, 1(Uh,i " u, Uh,i = Th,i) : 0 " u " s; h ∈ [[1; k]]; 1 " i " nh). Its predictable
variation process 〈Mh,i〉 is given by
∫ s
0
Yh,i(u)
(
λ˜P,h,i(u) + λE,h(u)
)
du. Note that S˜P,h,i is
(F0)−measurable so that we can define
dMwh (s)
def
=
nh∑
i=1
dMh,i(s)
S˜P,h,i(s)
= dNwE,h(s)− Y
w
h (s)λE,h(s)ds, (3)
and Mwh (s) is a local square integrable martingale with respect to (Fs)s.
Let ΛE and λE denote ΛE,h and λE,h under the null (∀h ∈ [[1; k]]). Then we have
dNwE,.(s) =
k∑
h=1
dNwE,h(s) =
k∑
h=1
dMwh (s) + λE(s)
k∑
h=1
Y wh (s)ds. (4)
Introducing (3) and (4) in formula (2), we obtain under the null
Zwh (T ) =
k∑
l=1
∫ T
0
1(Y w. (s) > 0)
(
δhl −
Y wh (s)
Y w. (s)
)
dMwl (s),
with δhl being the Kronecker delta. For all h ∈ [[1; k]], Zwh are local square integrable
martingales with respect to (Fs)s. We have E〈Zwh 〉(T ) <∞ since ∀h ∈ [[1; k]]
E〈Zwh 〉(T ) "
k∑
l=1
nlE
{∫ T
0
SC,l,1(s)SE(s)
S˜P,l,1
(
λ˜P,l,1(s) + λE(s)
)
ds
}
< ∞ (see Web Appendix
A). So the Zwh are square integrable over [0, T ].
As the first and second order moments of the Zwh exist, we have
cov
(
Zwh (T ), Z
w
j (T )
)
= E[Zwh , Z
w
j ](T ),
[Zwh , Z
w
j ](T ) =
k∑
l=1


∫ T
0
1(Y w. (s) > 0)
(
δhl −
Y wh (s)
Y w. (s)
)(
δjl −
Y wj (s)
Y w. (s)
) nl∑
i=1
dNl,i(s)(
S˜P,l,i(s)
)2

 .
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Note that, when k = 2, we have
[Zw1 , Z
w
1 ](T ) =
∫ T
0
1(Y w. (s) > 0)


(
Y w
2
(s)
Y w1 (s) + Y
w
2 (s)
)2 n1∑
i=1
dN1,i(s)(
S˜P,1,i(s)
)2
+
(
Y w
1
(s)
Y w
1
(s) + Y w
2
(s)
)2 n2∑
i=1
dN2,i(s)(
S˜P,2,i(s)
)2

 .
2.4 The test statistic
Following closely the usual log-rank test (Andersen et al., 1993), and knowing that
k∑
h=1
Zwh (T ) = 0, we propose to test the null hypothesis with the statistic
Uw(T ) = Zw
0
(T )tΣˆ2,w
0
(T )−1Zw
0
(T ), (5)
with Zw
0
(T ) =
(
Zw1 (T ), . . . , Z
w
k−1(T )
)t
and Σˆ2,w0 being the matrix of general term
σˆ2,wh,j (T ) =
k∑
l=1


∫ T
0
1(Y w. (s) > 0)
(
δhl −
Y wh (s)
Y w. (s)
)(
δjl −
Y wj (s)
Y w. (s)
) nl∑
i=1
dNl,i(s)(
S˜P,l,i(s)
)2


for (h, j) ∈ [[1; k − 1]]2.
Under the assumptions (1) we can show that, under the null, Uw(T ) ∼ χ2(k − 1) when
n −→ ∞ (see proof in Web Appendix B).
3. Stratified version of the test
We made the strong assumption of independence between TE andX to estimate the variance
of Zwh under the null. Now we look at the general case where TE and X can be depen-
dent. We define a set partition of the covariates set by (I1, . . . , Im) and we assume that
P (TEh > t | Xh) =
m∑
s=1
P (TEh > t | Xh ∈ Is). 1 (Xh ∈ Is), where Xh denotes the set of
covariates in the group h. The (Is)1"s"m are called strata of one or more covariate. When
cancer death is related to sex of patients, for example, we would consider 2 strata for men
and women. Thus we assume homogeneity within each stratum but we allow heterogeneity
between strata. We define ΛE,h,s as the cumulative excess hazard corresponding to the net
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survival function SE,h,s(t) = P (TEh > t |Xh ∈ Is).
We want to test (H0) : ∀t ∈ [0, T ] , ∀s ∈ [[1;m]] ΛE,1,s(t) = . . . = ΛE,k,s(t).
We define Y w.,s(u) =
k∑
h=1
Y wh,s(u) with Y
w
h,s(u) =
nh∑
i=1
Yh,i(u)
S˜P,h,i(u)
1(Xh,i ∈ Is). In the same way,
we define dNwE,.,s(u) =
k∑
h=1
dNwE,h,s(u). Following Andersen et al. (1993), we define the statis-
tics
Zwh,s(T ) =
∫ T
0
1(Y w.,s(u) > 0)dN
w
E,h,s(u)−
∫ T
0
1(Y w.,s(u) > 0)
Y wh,s(u)
Y w.,s(u)
dNwE,.,s(u), (6)
and
σˆ2,wh,j,s(T ) =
k∑
l=1
{∫ T
0
1(Y w.,s(u) > 0)
(
δhl −
Y wh,s(u)
Y w.,s(u)
)(
δjl −
Y wj,s(u)
Y w.,s(u)
)
×
nl∑
i=1
dNl,i(u)(
S˜P,l,i(u)
)21(Xl,i ∈ Is)

 . (7)
We denote for s ∈ [[1;m]] the vectors and matrices with elements given by (6) and (7) by Zws
and Σˆ
2,w
s . Then we will test the null hypothesis with the statistic(
m∑
s=1
Z
w
s,0(T )
)t
.
(
m∑
s=1
Σˆ
2,w
s,0 (T )
)
−1
.
(
m∑
s=1
Z
w
s,0(T )
)
,
which has asymptotic χ2 distribution with (k − 1) degrees of freedom under the null. Note
that, for s ∈ [[1;m]], Zws,0(T ) =
(
Zw1,s(T ), . . . , Z
w
k−1,s(T )
)t
and Σˆ
2,w
s,0 is the same matrix as
Σˆ
2,w
s without the last row and the last column.
4. Simulations
We evaluated the performance of the proposed log-rank type test by simulation studies in
the cases where TE and X were (1) independent when k = 2 and k = 3; and (2) dependent
when k = 2.
4.1 Data generation and simulations design
For each patient i, we independently generated covariates sex, age and G, which represents
the groups (G had k = 2 or k = 3 levels). Covariate sex was generated from a binomial
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distribution with P (man) = P (woman) = 1/2. Covariate G was generated to study balanced
cases (P (G = 0) = P (G = 1) when k = 2 or P (G = 0) = P (G = 1) = P (G = 2) when
k = 3) or unbalanced cases only when k = 2 (P (G = 0) = 1/4 and P (G = 1) = 3/4).
Because TP depends on age, we studied 3 scenarios : (1) in the first scenario, we generated
covariate age to represent approximately the empirical distribution of the ages of colon cancer
patients in the French registries (25 percent of patients aged 40-64 years, 35 percent aged
65-74 years, and 40 percent aged 75 years and over); (2) in the second scenario, we studied
a young population using a uniform distribution between 30 and 40; and (3) in the third
scenario we studied an old population using a uniform distribution between 65 and 80.
Danieli et al. (2012) showed that the multivariable modelling estimator, which is based on
the multivariable additive excess hazard model, is a consistent parametric estimator of net
survival when adjusting for demographic covariates. Thus, we generated survival times from
this model. In its classical additive form (Este`ve et al., 1990), the observed hazard related
to the individual time of death, Ti, is defined as the sum of the instantaneous conditional
population all-cause and excess hazards, λ˜P,i and λ˜E,i. Ti was generated as follows: firstly,
for each patient i, the time to death due to population hazard, TPi, was obtained from the
2004 American life table, survexp.us, stratified by Di = (agei, sexi), and provided by the
survival package in R software (Therneau, 2015). Secondly, for each patient i, the time
to death due to cancer, TEi , was obtained from λ˜E,i modelled with the standard approach
(see e.g. Giorgi et al., 2003) and using the inverse transformation method. More precisely,
λ˜E,i(t) = f(t). exp
(
βsex1(sexi = man) +
k−1∑
l=1
βG,l1(Gi = l)
)
where βsex and βG,l are the log
hazard ratios (HR) of the covariates. The baseline hazard function f was modelled with a gen-
eralized Weibull distribution (Belot et al., 2010) as t *−→
κρκtκ−1
1 +
(ρt)κ
α
with ρ = 0.5, α = 0.2 and
κ = 2. The distributions of net survival between the groups that are defined by the levels of G
vary when the effects of G on excess mortality vary. More precisely, the null is true when the
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HR(s) of G equal 1. Conversely, the farther the HR(s) are from 1, the more different are the
groups in terms of net survival and the farther we are from the null. When k = 2, the HR of G
belonged to {0.7; 0.8; 0.9; 1; 1.2; 1.4; 1.6}. When k = 3, the HRs of G, (HR1, HR2), belonged
to {(1, 0.7); (1, 1); (1, 1.2); (1, 1.4); (1, 1.6); (0.9, 1.2); (0.8, 1.4); (0.7, 1.6)}. When studying the
case where TE andX were independent, we did not introduce effects of age and sex on excess
mortality (assumption of homogeneity). Conversely, to study the case where TE andX were
dependent, we set the HR of sex equal to 2 and 3 and we chose to assume independence with
respect to age. But this could be done in the same way as done for sex. The bigger is the HR
of sex, the more different are the distributions of the time to death due to cancer between
men and women in the group h. Finally, individual censoring times, Ci, were generated
from a uniform distribution U [0; b], where the upper boundary b was selected to obtain
approximately 0% or 30% overall censoring levels. Then, each individual’s observable time
of death was Ti = min(TPi , TEi) whereas each individual’s observed time of death was
Ui = min(TPi , TEi, Ci). In addition, all subjects still at risk at 5 years were censored.
Moreover, we defined an individual’s hypothetical time of death as the minimum of the
excess death and censoring times. According to this time, we obtained another vital status
corresponding to the hypothetical world where cancer would be the only cause of death.
Thus, we could compare our test to the usual log-rank applied on data from hypothetical
world. We will refer to them as ”data from hypothetical world” and we will consider that the
usual log-rank on these data is the gold standard. This is only possible within a simulation
framework. Note that even if the cause specific data are available in our simulations, no
direct gold standards for our log-rank test can be calculated in the ”real world” since the
real world is that of the competing risks and so still subject to informative censoring.
Each simulation run consisted of 2000 independent samples. Each of them contained 1000
patients.
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4.2 Simulation results
Results obtained with no censoring were roughly equivalent to those obtained with 30%
censoring. So we show only those related to 30% censoring level.
When compared 2 groups, the estimation of the type I error of our log-rank type test was
good. In table 1, at a 5% level of significance, the confidence intervals for the estimation of
the type I error contain the nominal level of 5% for our test and the usual log-rank applied
on data from hypothetical world. In comparison with the usual log-rank, our test performed
well in terms of power (table 1). In the second scenario, where the patients under study are
young, the results were nearly the same for both tests. Nevertheless, there was a loss of power
for our proposed test in the first and the third scenarios. Note that in the first scenario there
were 75% of patients aged more than 65.
[Table 1 about here.]
As expected, whatever the scenario, both tests were more powerful when the number of
patients increased from 500 to 2000 (results not shown) and they lost power when the cases
were unbalanced (Web Table A).
When studying the comparison of 3 groups, the estimation of the type I error was close to
the nominal level of 5% (table 2). In terms of power, in the first scenario, table 2 shows
that our proposed test performed worse than the usual log-rank in the hypothetical world,
especially when the 3 distributions of net survival were not really away from each other
((HR1, HR2) = (1, 0.7) or (0.9, 1.2)). In the other cases, the results of both tests were as
powerful. In addition, as previously, our test had a similar power as the usual log-rank when
patients were young and we observed a loss of power in scenarios 1 and 3 (Web Table B).
[Table 2 about here.]
When studying the comparison of 2 groups when TE and the covariate sex were dependent,
we compared results from the stratified version of our test with the not-stratified version. As
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expected, there was a loss of power when using the test which was not stratified (table 3). The
farther βsex is from 0, the bigger was this loss of power. More interestingly, as shown in table 3,
when the conditional distributions of TE were the most different (HRsex = 3), the estimation
of the type I error was equal to 2.95, 95% Confidence Interval (CI) = [2.21; 3.69], when using
the not stratified version of our test vs 4.60, 95%CI = [3.68; 5.52], with the stratified version.
However, it was equal to 4.80, 95%CI = [3.86; 5.74], vs 5.45, 95%CI = [4.46; 6.44], when
HRsex = 2. Thus, the stratified log-rank type test has to be used when the stratum variable
has an important impact on net survival.
[Table 3 about here.]
5. Application
We applied the proposed test in one application for illustration. This analysis considered
survival data on 10,108 patients with colorectal cancer diagnosed in 1998. These data came
from 17 US registries obtained from the Surveillance, Epidemiology, and End Results (SEER)
Program (2006) in the US. From this cohort, we excluded 816 patients who had no surgical
procedure of the primary site, 2 patients in whom the use of a surgical procedure was
not certain, and 167 patients with in situ tumors. Patient follow-up was restricted to the
first five years after diagnosis and censoring set at five years in still alive patients. This
left 9,123 patients for analysis. The covariates used were age at diagnosis, sex, ethnicity
(black or white), and cancer stage at diagnosis (in four stages I to IV according to the stage
classification of the American Joint Committee on Cancer used by SEER registries (SEER
Program: comparative staging guide for cancer, 1993)). This data set is described in Web
Table C.
We used the American life tables provided by R software survexp.usr, that is to say life
tables stratified by age, sex, ethnicity and calendar year, from 1998 to 2003. All the analyses
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were computed using R (R Core Team, 2014). The code and the .RData files are available
upon request.
We used our test to compare net survival distributions between Black and White patients
stratified on stage, which is known to have an important effect on net cancer survival.
Moreover in net survival framework age is a strong prognostic factor in several types of
cancer (Bossard et al., 2007). We built three age groups to have adults and young old patients
(20-69 years), old patients (70-79 years) and very old patients (! 80 years). We stratified
also on these groups thereby obtaining 12 strata. Figure 1 shows the impact of age and most
importantly of stages on net survival for these real data. Firstly using a test not stratified
produced a test statistic equal to 19.95 (p-value = 7.9 × 10−6). Secondly when running
our test stratified on stage, we found a test statistic equal to 5.42 (p-value = 0.0199). The
lower proportion of Black patients in lower stages (47% in stages I-II vs. 56% for White
patients) suggested later diagnosis, but even after correcting for this, the impact of ethnicity
on cancer mortality remained significant and higher for Black patients. Thirdly when running
our test stratified on age, we found a test statistic equal to 23.62 (p-value = 1.2 × 10−6).
Whatever the age group, differences between net survival of Black and White patients were
indeed bigger considering age strata rather than stage strata (data not shown). Finally
when running our test stratified on both age and stage, we found a test statistic equal
to 9.92 (p-value = 0.0016). Thus not stratifying on stage overestimated the differences
between net survival distributions of Black and White people whereas not stratifying on age
underestimated these differences. Stratifying on both provided the ”true” differences which
had been first distorted by heterogeneity between groups. Note that using the log-rank test
on observed survival led to a test statistic equal to 19.5. So using net survival instead of
observed survival allowed to remove the confounding effect of age on observed survival.
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[Figure 1 about here.]
6. Discussion
Our proposed test compares distribution of net survival estimated by the Pohar-Perme
estimator (Perme et al., 2012). The simulation study showed that the estimation of the
type I error is correct. Our test also performs well in terms of power even if we observed a
loss of power when the studied patients were old. This loss of power could be explained by
the fact that elderly patients have higher expected mortality rates, that is to say there are
more deaths due to other causes. Thus, there is a loss of information and higher variability
in the estimates of net survival.
The stratified version is useful when dealing with covariates impacting strongly on net
survival, that is to say when there is one or more covariate having different distributions
in the groups to compare (see e.g. Aalen et al., 2008, p. 110-111). The decision to use the
stratified version should be based on epidemiological considerations depending on studied
covariates. The application on real data showed that part of difference in net cancer survival
between Black and White patients is due to differences in stages.
We took the same set of assumptions as in Perme et al. (2012). TE and TP being two
latent times defined on the same individual, they could be dependent conditionally on the
covariates only via some unmeasured covariates (e.g. deprivation or smoking habits of the
same individual). In addition, we made assumptions (1) in the proof of the asymptotic
distribution of the statistic under the null. These are reasonable assumptions on follow-up
time because they require to use small follow-up times compared with TP given D or TE.
A possible limitation of our work is that we only studied simulations favourable to our
test. Indeed, the usual log-rank is optimal under the assumption of proportional hazard
rates but performs poorly when this assumption does not hold (Qiu and Sheng, 2008).
Several approaches have been proposed to deal with this problem (see e.g. Fleming et al.,
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1980; Mantel and Stablein, 1988 ; Breslow, Edler, and Berger, 1984; Qiu and Sheng, 2008).
Further studies are needed to adapt our proposed test starting from one of these procedures.
In addition, the formula we proposed was developed with a continuous underline process
(without ties). Nevertheless, event times are usually assumed to be discrete when testing
(Aalen et al., 2008). In our application, there were 46% of ties between event times since
only survival in months was available from the SEER. We studied the impact of the use of
a non tie-corrected version of our test by simulation rounding survival times to obtain 38%,
45% and 54% of ties. Comparing the percentages of rejection of the null running the test
on the same dataset with and without ties led to a maximum difference of 2% (results not
shown). Thus using a non tie-corrected version of the test had hardly any impact with such
percentages of ties. However a tie-corrected estimator adapted from the one presented by
Andersen et al. (1993) may be of interest.
Another option to compare distributions of net survival is to use regression modelling. We
compared our proposed test with the likelihood ratio test from the multivariate excess
mortality model using simulations datasets, both presented in section 4.1. We assumed
an excess mortality model perfectly defined, i.e. adjusted on G and sex (if needed) with
proportional effect (results not shown). In terms of power, the biggest difference between the
percentages of rejection of the null hypothesis at the 5% level of significance for the 2 tests
was 3.15 in favour of the likelihood ratio test. However, with our proposed test, we did not
have to deal with the model-building strategy (see e.g. Wynant and Abrahamowicz, 2014)
within this known setting. Therefore, our non parametric test should be preferred because
of its simplicity.
Since our test compares favorably with the usual log-rank on data from hypothetical world,
as shown in the simulation study, it may be helpful for cancer registries to compare net
cancer survival between countries or areas. In addition, it may be applied to other chronic
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diseases for which net survival should be used. In the same way Schoenfeld (1981) did with
the usual log-rank, it would be interesting to determine the distribution of the test statistic
under the alternative hypothesis. Then deriving his formula, we could obtain the sample
size providing the minimal detectable difference. Another perspective would be based on the
equivalence between the usual log-rank and the score test from a Cox model. Introducing
in a Cox model time dependent weights corresponding to the ones used in the Pohar-Perme
estimator could be an interesting approach to investigate.
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Figure 1. Net survival estimated by the Pohar-Perme estimator according to stage and
age groups for: , White patients; , Black patients. When the excess hazard is close
to 0 and/or when the number at risk is low, the variability of the Pohar-Perme estimator
can cause non-monotonic net survival curves.
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Table 1
Comparison of 2 groups: percentage of rejection of the null hypothesis at the 5% level of significance for 2000
simulations of 1000 patients. Distribution of age specific to each scenario: Scenario 1: 25% aged [40− 64], 35% aged
[65− 74], and 40% aged [75− 85]; Scenario 2: 30 " age " 40 (uniform); Scenario 3: 65 " age " 80 (uniform).
HRa Percentage of rejection of the following tests (95%CI)
Proposed test
Usual log-rank on data from
hypothetical world
Scenario 1: balanced caseb
0.7 81.50 (79.80;83.20) 93.05 (91.94;94.16)
0.8 44.85 (42.67;47.03) 59.85 (57.70;62.00)
0.9 15.55 (13.96;17.14) 20.35 (18.59;22.11)
1 5.20 (4.23;6.17) 5.30 (4.32;6.28)
1.2 35.95 (33.85;38.05) 46.70 (44.51;48.89)
1.4 88.30 (86.89;89.71) 95.05 (94.10;96.00)
1.6 99.50 (99.19;99.81) 100 (99.81;100)
Scenario 2: balanced caseb
0.7 91.80 (90.60;93.00) 92.20 (91.02;93.38)
0.8 56.90 (54.73;59.07) 57.60 (55.43;59.77)
0.9 18.15 (16.46;19.84) 18.25 (16.56;19.94)
1 4.15 (3.28;5.02) 4.35 (3.46;5.24)
1.2 47.80 (45.61;49.99) 48.45 (46.26;50.64)
1.4 94.90 (93.94;95.86) 95.30 (94.37;96.23)
1.6 99.90 (99.64;99.97) 99.90 (99.64;99.97)
Scenario 3: balanced caseb
0.7 82.20 (80.52;83.88) 92.00 (90.81;93.19)
0.8 47.85 (45.66;50.04) 58.75 (56.59;60.91)
0.9 13.85 (12.34;15.36) 17.10 (15.45;18.75)
1 5.35 (4.36;6.34) 4.30 (3.41;5.19)
1.2 39.20 (37.06;41.34) 48.75 (46.56;50.94)
1.4 88.20 (86.79;89.61) 95.25 (94.32;96.18)
1.6 99.10 (98.69;99.51) 99.85 (99.56;99.95)
a: Hazard Ratio of the level of G on excess mortality used in data generation, where G is
the covariate representing the groups;
b: Balanced cases correspond to the cases where groups are similar in size with
P (G = 0) = P (G = 1).
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Table 2
Comparison of 3 groups: percentage of rejection of the null hypothesis at the 5% level of significance for 2000
simulations of 1000 patients. Distribution of age (scenario 1): 25% aged [40− 64], 35% aged [65− 74], and 40% aged
[75− 85].
(HR1, HR2)a Percentage of rejection of the following tests (95%CI)
Proposed test
Usual log-rank on data from
hypothetical world
Scenario 1: balanced caseb
(1, 0.7) 66.75 (64.69;68.81) 82.90 (81.25;84.55)
(1, 1) 5.10 (4.14;6.06) 4.95 (4.00;5.90)
(1, 1.2) 26.20 (24.27;28.13) 35.80 (33.70;37.90)
(1, 1.4) 74.65 (72.74;76.56) 87.35 (85.89;88.81)
(1, 1.6) 97.20 (96.48;97.92) 99.70 (99.46;99.94)
(0.9, 1.2) 42.40 (40.23;44.57) 58.20 (56.04;60.36)
(0.8, 1.4) 96.10 (95.25;96.95) 98.90 (98.44;99.36)
(0.7, 1.6) 100 (99.81;100) 100 (99.81;100)
a: Hazard Ratios of the levels of G on excess mortality used in data generation, where G is
the covariate representing the groups;
b: Balanced cases correspond to the cases where groups are similar in size with P (G = 0) =
P (G = 1) = P (G = 2).
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Table 3
Comparison of 2 groups: percentage of rejection of the null hypothesis at the 5% level of significance for 2000
simulations of 1000 patients when sex has an impact on excess mortality in the data generation. Distribution of age
specific to scenario 1: 25% aged [40− 64], 35% aged [65− 74], and 40% aged [75− 85].
HRa Percentage of rejection of the following tests (95%CI)
Proposed stratified test Proposed test (not stratified)
Scenario 1: HRsex = 2
0.7 90.60 (89.32;91.88) 88.55 (87.15;89.95)
0.8 57.90 (55.74;60.06) 53.25 (51.06;55.44)
0.9 18.00 (16.32;19.68) 16.40 (14.78;18.02)
1 5.45 (4.46;6.44) 4.80 (3.86;5.74)
1.2 46.50 (44.31;48.69) 43.50 (41.33;45.67)
1.4 95.00 (94.04;95.96) 93.35 (92.26;94.44)
1.6 99.90 (99.64;99.97) 99.85 (99.56;99.95)
Scenario 1: HRsex = 3
0.7 93.70 (92.74;94.76) 88.30 (86.89;89.71)
0.8 61.80 (59.67;63.93) 51.25 (49.06;53.44)
0.9 18.25 (16.56;19.94) 14.15 (12.62;15.68)
1 4.60 (3.68;5.52) 2.95 (2.21;3.69)
1.2 50.30 (48.11;52.49) 40.90 (38.75;43.05)
1.4 95.35 (94.43;96.27) 91.40 (90.17;92.63)
1.6 100 (99.81;100) 99.90 (99.64;99.97)
a: Hazard Ratios of the levels of G on excess mortality used in data generation, where G is
the covariate representing the groups.
